Hansoh Pharma

Biomarkers

• EGFR exon 19 deletion / L858R5
• KRAS G12C4
• EGFR exon 20 insertion1
• KRAS G12D1
• RET fusion or mutation1

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

aumolertinib 5adebrelimab 3tislelizumab 1SHR-A2009 1HS-20093 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

• 2027-08 A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Phase 2 · RET fusion or mutation

Trials

14 of 19 trials shown

1. A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

   Not yet recruiting Phase 3 Hansoh Pharma Started 2026Primary completion 2030-05 NCT07822542

   HS-10370adebrelimabcisplatincarboplatinpemetrexedtislelizumab

   Documentation of the presence of a KRAS G12C mutation

   KRAS G12CCarcinoma, Non-Small-Cell Lung

2. Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

   Active, not recruiting Phase 3 Hansoh Pharma Started 2021Primary completion 2024-06 NCT04923906

   aumolertinib

   …arbors 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations assessed by central tes…

   EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer

3. Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

   Active, not recruiting Phase 3 Hansoh Pharma Started 2021Primary completion 2024-07 NCT04687241

   aumolertinib

   …bors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.

   EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer

4. A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

   Recruiting Phase 3 Hansoh Pharma Started 2021Primary completion 2024-07 NCT04951635

   aumolertinib

   …rs one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19Del, L858R), either alone or in combination with other EGFR mutations including T790M, assess…

   EGFR exon 19 deletion / L858RStatus may be outdated, last updated 2022-06-16Non-small Cell Lung Cancer

5. A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

   Recruiting Phase 2 Hansoh Pharma Started 2023Primary completion 2027-08 NCT06147570

   HS-10365 capsules

   …gically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC with RET fusion-positive, including recurrent or initial diagnosed Stage IIIB-IIIC/IV NSCLC that is not s…

   RET fusion or mutationStatus may be outdated, last updated 2023-11-27Nonsmall Cell Lung Cancer

6. An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer

   Not yet recruiting Phase 1 Hansoh Pharma Started 2026Primary completion 2026-11 NCT07685041

   midazolam

   Confirmed EGFR mutation positivity in participants before enrollment.

   EGFR exon 19 deletion / L858RNSCLC

7. A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

   Not yet recruiting Phase 1 Hansoh Pharma Started 2026Primary completion 2027-04 NCT07414953

   HS-10504SHR-A2009HS-20122HS-20117SHR-1826SHR-A2102

   Cohort1:participants with EGFR mutation advanced stage NSCLC，disease progression on or after prior treatment；

   EGFR exon 19 deletion / L858RLung Cancer

8. Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.

   Not yet recruiting Phase 1 Hansoh Pharma Started 2026Primary completion 2029-06 NCT07615413

   HS-10541

   …-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.

   KRAS G12CKRAS G12C Mutation Advanced Solid Tumor

9. A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC

   Recruiting Phase 1 Hansoh Pharma Started 2025Primary completion 2025-10 NCT06926413

   aumolertinibmidazolam

   …nti-tumor systemic therapy, and the tumor must harbor at least one of the EGFR mutations (ex19del or L858R, single mutation or combined with other EGFR mutations are both acceptable).

   EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer

10. A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

    Not yet recruiting Phase 1 Hansoh Pharma Started 2025Primary completion 2028-12 NCT06963502

    HS-10370HS-20117adebrelimabcapecitabineoxaliplatinleucovorinfluorouracilirinotecanHS-20093cisplatincarboplatin

    Documentation of the presence of a KRAS G12C mutation

    KRAS G12CAdvanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer

11. A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors

    Not yet recruiting Phase 1 Hansoh Pharma Started 2025Primary completion 2029-04 NCT06963398

    HS-10529

    A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors

    KRAS G12DAdvanced Solid Tumors

12. A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

    Recruiting Phase 1 Hansoh Pharma Started 2024Primary completion 2025-08 NCT07130916

    aumolertinib

    …nti-tumor systemic therapy, and the tumor must harbor at least one of the EGFR mutations (ex19del or L858R).

    EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer

13. A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

    Not yet recruiting Phase 1 Hansoh Pharma Started 2024Primary completion 2026-10 NCT06594874

    HS-10370adebrelimabcisplatincarboplatinpemetrexed

    Documentation of the presence of a KRAS G12C mutation

    KRAS G12CStatus may be outdated, last updated 2024-09-19Non-Small Cell Lung Cancer, Advanced Solid Tumors

14. A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

    Not yet recruiting Phase 1 Hansoh Pharma Started 2023Primary completion 2025-07 NCT05940116

    HS-20117

    …a study: Participants with locally advanced or metastatic NSCLC (stage IIIB/IIIC/IV) with EGFR-activating mutations who have progressed after or are intolerant to or not available to standard of care (SoC…

    EGFR exon 19 deletion / L858REGFR exon 20 insertionStatus may be outdated, last updated 2023-07-12Non-Small Cell Lung Cancer, Solid Tumor

No trials match these filters.